Nine Weeks of Immunotherapy Keeps Colon Cancer Patients Relapse-Free
In a UK-led trial, colon cancer patients with a specific genetic subtype who received just nine weeks of the immunotherapy pembrolizumab before surgery have stayed cancer-free for nearly three years, with zero relapses so far.